Bafna Pharmaceuticals Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Mar ' 23	Mar ' 22	Mar ' 21	Mar ' 20	Mar ' 19

Sources of funds

Owner's fund

Equity share capital

23.66

23.66

23.66

2.37

23.66

Share application money

-

-

-

55.36

-

Preference share capital

-

-

-

-

-

Reserves & surplus

49.80

39.22

33.11

-6.78

-2.86

Loan funds

Secured loans

22.92

7.89

2.50

3.02

46.23

Unsecured loans

-

-

-

-

-

Total

96.38

70.77

59.27

53.96

67.02

Uses of funds

Fixed assets

Gross block

94.66

87.94

79.57

74.09

72.87

Less : revaluation reserve

-

-

-

-

-

Less : accumulated depreciation

54.43

49.09

43.60

39.12

35.85

Net block

40.23

38.85

35.97

34.97

37.02

Capital work-in-progress

1.50

-

0.83

0.21

-

Investments

-

-

-

-

1.43

Net current assets

Current assets, loans & advances

87.85

51.40

49.67

35.88

82.19

Less : current liabilities & provisions

33.20

19.47

27.19

17.10

53.62

Total net current assets

54.65

31.93

22.47

18.78

28.57

Miscellaneous expenses not written

-

-

-

-

-

Total

96.38

70.77

59.27

53.96

67.02

Notes:

Book value of unquoted investments

-

-

-

-

1.43

Market value of quoted investments

-

-

-

-

-

Contingent liabilities

10.48

2.42

-

-

-

Number of equity sharesoutstanding (Lacs)

236.56

236.56

236.56

23.66

236.56